Articles tagged with Cancer Medication
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Researchers plan an international project to analyze cancer-related proteins, enabling tailored treatments. The initiative could lead to improved treatment outcomes within 5 years of completion.
Researchers at Baylor College of Medicine discovered that thioredoxin-like 2 is highly expressed in cancer cells and helps protect them from oxidative stress. This protein plays a crucial role in cancer cell growth and survival, making it a promising target for future anti-cancer therapies.
Researchers have identified two FDA-approved cancer drugs that can inhibit NOD2's activity, offering a new avenue for treating Crohn's disease and sarcoidosis. The medications target the NOD2:RIP2 pathway, potentially alleviating symptoms and improving outcomes for patients with these conditions.
Cancer treatment decisions will be based on biology as medical oncologists need skills and knowledge to implement personalized medicine. Governments, companies, and clinicians must adapt drug development with targeted patient selection, shorter trials, and cost-effectiveness improvements.
A research team has pinpointed a novel cancer gene called COT (MAP3K8) as a key player behind drug resistance in melanoma. The study provides a framework for discovering ways to tackle cancer drug resistance and identifies potential targets for new treatments.
Researchers have found that patients with BRAF-mutated melanoma develop resistance to targeted treatment PLX4032 through genetic mutations or cell surface protein overexpression, accounting for 40% of cases. The study aims to develop new therapies targeting these mechanisms.
Scientists at the University of Strathclyde and Glasgow are using a £1 million grant to investigate the causes of serious diseases like heart disease, stroke, and high blood pressure.
Researchers have identified a new target for stopping tumors from developing their own blood supply, with a newly developed drug called ACE-041 showing promising results in advanced cancer patients. The drug targets the ALK-1 receptor and has been shown to halt tumor progression and improve patient outcomes.
A new anti-cancer drug, inecalcitol, has shown encouraging responses in men with hormone-resistant prostate cancer. In a phase II(a) clinical trial, 83% of patients responded to the treatment with a drop in PSA levels of 30% or more within three months.
In a Phase I trial, MK-4827 demonstrated anti-tumour responses in both sporadic and BRCA1/2 mutation-associated cancers. Patients with exhausted standard therapies showed significant shrinkage or stabilization of tumours for extended periods.
Using OncoMap, researchers can identify specific mutations in oncogenes that drive ovarian cancer growth and choose targeted drugs to halt tumor progression. The technique holds promise for personalized medicine in treating advanced ovarian cancer.
Researchers found that using erythropoietis-stimulating drugs with Herceptin resulted in reduced effectiveness of the cancer treatment. The study suggests that these drugs may activate similar downstream pathways as trastuzumab, causing antagonism between the two treatments.
Joshua Kritzer's $1.5 million grant will fund rapid drug-screening process to identify new cancer treatments. Cyclic peptides, produced using baker's yeast, can bind with disease-causing proteins that are difficult to target.
Dr Guillaume Lessene has been awarded the Walter and Eliza Hall Institute's inaugural de Burgh Fellowship to translate research findings into new cancer treatments. The $AUD150,000 fellowship supports his work on developing inhibitors for Bcl-2 proteins and other targets, with the goal of treating various types of cancer.
A new study found that romiplostim, a drug mimicking the effects of thrombopoietin, is more effective than standard care in treating immune thrombocytopenia. The treatment significantly improved platelet levels and reduced the need for splenectomy in patients, enhancing their quality of life.
A study by Oregon State University researchers found that low birth weight can cause lifelong problems processing medications. The kidneys of underweight animals had significantly less ability to process and transport drugs due to a protein called a 'drug transporter'.
Researchers analyzed data from the Cancer Prevention Study II Nutrition Cohort and found that long-term statin use was not associated with overall cancer incidence or increased risk of common types of cancer. Instead, it was linked to lower risks of melanoma, endometrial cancer, and non-Hodgkin lymphoma.
Researchers identify FOXM1 as a key player in initiating human cancer by exploiting the self-renewal property of stem cells, leading to excessive cell growth and pre-cancerous conditions. The study aims to translate these findings into molecular diagnostic tests and anti-tumour drugs.
Researchers at Northwestern University have found that a soy-based drug can prevent the movement of prostate cancer cells from the prostate to the rest of the body. The experimental treatment, genistein, has shown beneficial effects on human subjects with localized prostate cancer in a recent phase II study.
Researchers at Georgetown University Medical Center found no conclusive evidence linking joint complaints to inflammatory arthritis or autoimmune disease in women taking aromatase inhibitors. However, they suggest encouraging women to continue taking the medication despite joint pain.
Researchers create a nanobioconjugate drug that specifically targets glioblastoma multiforme by blocking the production of laminin-411, promoting tumor cell death. Human clinical trials are anticipated to begin soon, offering new hope for brain cancer treatment.
A team of researchers has discovered a way to target and block the enzyme beta glucuronidase, which causes severe diarrhea in patients taking CPT-11, a widely used colon cancer treatment. The breakthrough approach could improve anticancer drug efficacy and tolerance without harming beneficial gut bacteria.
Researchers found a Japanese asthma drug can stop the spread of breast cancer cells and reduce tumour growth by 50%. Tranilast targets a molecule in cancer cells that binds to the aryl hydrocarbon receptor, making it beneficial for treating allergies, inflammatory diseases, and cancer.
A recent study found a decline in unnecessary care for prostate cancer patients not likely to benefit from treatment after Medicare policy changes reduced reimbursement. In contrast, patients with clear benefits from the therapy continued to receive it at the same rate.
Researchers suggest using digitized personal health records (PHR) to improve chronic disease management, increasing patient engagement and reducing hospital visits. A PHR portal-type system could facilitate dialogue between patients and healthcare workers, leading to better overall health outcomes.
Researchers found that NSAIDs like aspirin trigger programmed cell death in abnormal stem cells, preventing colon cancer. This discovery could lead to new strategies for protecting people at high risk of the disease.
Cancer Discovery is a new peer-reviewed journal from the American Association for Cancer Research (AACR), featuring game-changing research and review articles. The journal combines expertise from founding Editors-in-Chief Lewis C. Cantley and José Baselga, with executive editor Mark W. Landis.
Researchers identified two small-molecule inhibitors that effectively targeted FAK, an enzyme present in certain cancers. These inhibitors, Y11 and Y30, inhibited colon cancer-cell growth and decreased tumor formation, offering a potential for more effective and less toxic cancer therapies.
Tumor cells can escape chemotherapy by hiding in the thymus, an organ where immune cells mature, and are bathed in growth factors that protect them from drugs' effects. Researchers plan to test drugs that interfere with these protective factors to prevent cancer relapse.
A study published in the New England Journal of Medicine found that over half of patients with a specific type of lung cancer responded well to a new targeted treatment called crizotinib. The medication targets the gene driving the cancer and has been shown to improve patient outcomes, including reduced tumor growth and improved qualit...
A new oral drug causes dramatic shrinkage of a rare, aggressive form of soft-tissue cancer driven by an abnormally activated protein. The findings highlight the value of personalized medicine gene-testing strategies to predict best drug treatment for individual cancers.
A clinical trial found that daily doses of crizotinib shrank tumors in over half of patients with ALK-rearranged non-small-cell lung cancer, and suppressed growth in another one-third. The treatment has been shown to significantly improve symptoms and quality of life for these patients.
A study suggests that plant stem cells derived from trees could be used to produce the anticancer compound paclitaxel at a low cost. This method avoids the use of mature trees and environmentally damaging by-products associated with current industrial manufacturing processes.
The updated guideline advises physicians to discuss individual risks and benefits of ESAs with cancer patients, recommending cautious use due to associated risks of thromboembolism and tumor progression. ESAs are still effective in reducing red blood cell transfusions, which can impact quality of life.
A project led by Mr Hemant Kocher aims to target the stroma surrounding pancreatic cancer tumours, which is believed to drive tumour growth and prevent drug treatments from reaching the tumour. The research may lead to new drug targets for treating pancreatic cancer, a disease with poor survival rates.
Researchers are conducting a phase II clinical trial using reovirus, a common virus that causes mild symptoms, to target and kill specific tumor cells with KRAS or EGFR mutations. The goal is to exploit the virus's ability to replicate in cancer cells while minimizing harm to healthy cells.
A research team at Brown University has discovered a key chemical process involved in the development of cancer, particularly breast cancer. The study found that prolactin receptors can come together to form a structure that picks up growth factors leading to cancerous growth.
Researchers at Fox Chase Cancer Center found that the loss of protein Nedd9 initially slows cancer formation but then makes tumors more aggressive. A class of drugs already used in clinics can make these aggressive tumors more sensitive to treatment.
A redesigned microchip-based device, HB-Chip, captures more than 90% of cancer cells from blood samples, improving upon the original CTC-Chip. The new device also identifies previously unseen clusters of tumor cells, providing valuable insights into metastasis and targeted cancer therapies.
A randomized study found that adding topotecan to carboplatin and paclitaxel did not improve progression-free survival in patients with ovarian cancer, but increased toxicity. The standard regimen of carboplatin and paclitaxel remains the best care for epithelial ovarian cancer.
Researchers found that cancer patients across all stages exhibit a high burden of somatic symptoms, including fatigue, pain, and insomnia. These symptoms significantly impair daily functioning and overall well-being, highlighting the need for comprehensive symptom management strategies.
A Phase-II trial investigating pazopanib for relapsed/refractory urothelial cancer has generated promising results, with four patients experiencing tumor shrinkage and twelve seeing their metastases die due to 'necrotic evolution'. Researchers are eager to translate this activity into a survival advantage.
A Phase II study of the new-generation lung cancer drug PF-299 has shown impressive results in preventing disease progression when administered as a first-line treatment in patients with advanced disease. The study found that 85% of patients with EGFR mutations remained progression-free for at least nine months.
A Phase IIb/III trial shows afatinib benefits patients with lung adenocarcinoma whose cancer progressed after chemotherapy and erlotinib or gefitinib. Patients receiving afatinib experienced delayed disease progression and greater tumor shrinkage, but no significant difference in overall survival.
A Phase II clinical trial of MLN8237, a selective Aurora A kinase inhibitor, demonstrates single-agent activity with durable disease control in some patients with ovarian cancer resistant to platinum-based chemotherapy. The study found encouraging responses in several patients, suggesting potential for future combination therapies.
Scientists have determined the three-dimensional structure of CXCR4, a molecule involved in HIV infection and many forms of cancer. The high-resolution structure sheds light on how CXCR4 functions and could point to ways to control its activity.
The MU College of Veterinary Medicine is conducting a study to examine the efficacy of Attaxol in dogs with naturally occurring cancer. The study aims to determine the optimal dose and treatment duration for this cancer drug, which was developed specifically for canine use.
Onconova Therapeutics has agreed with the FDA on a Special Protocol Assessment (SPA) for its Phase 3 trial of Estybon in patients with myelodysplastic syndromes. The trial is expected to begin in Q4 2010 and will compare Estybon to Best Supportive Care.
Researchers have discovered that over-activation of the c-Abl protein can shut down parkin's protective function, leading to a build-up of toxic proteins and neuron death. Inhibiting c-Abl with existing drugs like imatinib may provide a new treatment approach for Parkinson's disease.
A molecular imaging technique may help identify early response to treatment in cisplatin-resistant ovarian cancer, potentially reducing unnecessary side effects and offering more effective treatments. Researchers used a PET probe to monitor tumor growth in mice with human ovarian cancer.
Researchers discuss factors contributing to cancer disparities, including language barriers and lack of health literacy. Successful strategies include tailoring messages to specific audiences and promoting evidence-based programs like Body and Soul.
Researchers propose a new approach to combat cancer and autoimmune diseases by targeting the balance between NF-kB and p53 signaling pathways. This balance is believed to be a promising target for developing new drugs, with potential benefits including improved disease treatment outcomes.
A phase 3 trial shows cabazitaxel improves overall and progression-free survival in men with advanced multi-drug resistant prostate cancer. The medication was found to be effective in patients whose disease progressed after standard chemotherapy with docetaxel.
Researchers engineered E. coli bacteria to produce taxadiene, a precursor to the cancer drug Taxol, achieving 1,000 times more production than previous strains. The technique could bring down manufacturing costs and help discover new therapeutic compounds for cancer and other diseases.
USC professor Andrea Armani is developing a real-time nanolaser instrument to locate carcinogens and their induced changes in living cells. This technology aims to create personalized cancer drug delivery systems, potentially within 10-15 years.
Researchers have uncovered a key mechanism in which leukemia cells trigger a protective response when exposed to histone deacetylase inhibitors. By disrupting this pathway, the cancer-killing capacity of HDACIs can be increased dramatically.
The NIH Director's Transformative Research Projects (T-R01) award program provides funding for exceptionally innovative research ideas that have the potential for extraordinary impact. The program allows investigators to sidestep conventional stumbling blocks and propose daring ideas.
A recent study found that the majority of US adults lack sufficient information to make the best medical decisions. To address this issue, doctors need to help patients prepare better for health decisions. Key findings include the importance of informed consent and patient decision aids in ensuring patients' preferences are respected.
A new immunotherapy treatment has improved two-year survival rates for high-risk neuroblastoma patients by 20 percent compared to standard treatment. Researchers report a higher cure rate, but also more pain and toxic side effects.
A new clinical trial found that 96% of patients with intermediate-risk neuroblastoma survived for three years after receiving reduced chemotherapy doses. The study, led by Katherine Matthay at UCSF Benioff Children's Hospital, aimed to minimize the toxic effects of cancer drugs on young children.